Biomarkers for parkinsonian disorders in CNS-originating extracellular vesicles

中枢神经系统来源的细胞外囊泡中帕金森病的生物标志物

基本信息

  • 批准号:
    10662918
  • 负责人:
  • 金额:
    $ 237.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

Summary Many cases of Parkinson’s disease, and even more so atypical parkinsonian disorders, are misdiagnosed. Misdiagnosis not only causes high stress and anxiety to patients, their families, and their caregivers, but also is a major impediment to development of effective therapy for these diseases. Recently, we have demonstrated that the α-synuclein concentration in extracellular vesicles (EVs) immunoprecipitated from serum or plasma using oligodendroglial and neuronal markers, and in particular the ratio between the α-synuclein concentrations in the two types of EVs, is a sensitive biomarker for distinguishing between Parkinson’s disease and multiple system atrophy. This liquid biopsy approach requires only a minimally invasive blood draw and could lead to a major advancement in developing diagnostic tests for these diseases. Here, we propose to build upon these recent findings by constructing a biomarker panel, including several additional candidate markers, and apply the panel to two additional atypical parkinsonian syndromes—progressive supranuclear palsy and corticobasal syndrome. Serum samples for the study will be obtained from several national biorepositories as well as collected locally, prospectively, in expert clinics. The study design emphasizes biomarker analysis within the first two years of diagnosis, and in prodromal synucleinopathy, to test the utility of the biomarker panel when it is most needed. An additional goal of the project is to develop methodology for validating the cellular origin of the EVs, an urgent unmet need in the field. Success of the project will lead both to an advancement of research on biomarkers for CNS diseases using a minimally invasive liquid biopsy that can be translated into clinical use in the near future.
总结 许多帕金森氏症病例,甚至更多的非典型帕金森氏症,被误诊。 误诊不仅会给患者、家属和护理人员带来巨大的压力和焦虑, 这是发展这些疾病的有效疗法的主要障碍。最近,我们证明了 使用免疫沉淀法从血清或血浆中免疫沉淀细胞外囊泡(EV)中的α-突触核蛋白浓度, 少突胶质细胞和神经元标记物,特别是α-突触核蛋白浓度之间的比率, 两种类型的EV,是区分帕金森病和多系统的敏感生物标志物 萎缩这种液体活检方法只需要微创抽血, 在开发这些疾病的诊断测试方面取得了进展。在这里,我们建议在这些最近的基础上, 通过构建生物标志物面板,包括几个额外的候选标志物,并应用面板, 另外两种非典型帕金森综合征-进行性核上性麻痹和皮质基底综合征。 本研究的血清样本将从几个国家生物储存库以及当地采集, 前瞻性地,在专家诊所。该研究设计强调在前两年内的生物标志物分析, 诊断,并在前驱突触核蛋白病,以测试的效用时,它是最需要的生物标志物面板。 该项目的另一个目标是开发验证电动汽车细胞起源的方法,这是一个紧迫的问题。 外地未满足的需求。该项目的成功将推动生物标志物的研究, CNS疾病使用微创液体活检,可以转化为临床使用在不久的将来。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Recent advances and future therapy development for Alzheimer's disease and related disorders.
阿尔茨海默病及相关疾病的最新进展和未来治疗发展。
  • DOI:
    10.4103/1673-5374.391182
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Hong,Megan;Bitan,Gal
  • 通讯作者:
    Bitan,Gal
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GAL BITAN其他文献

GAL BITAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GAL BITAN', 18)}}的其他基金

Can diagnostic biomarkers for parkinsonian syndromes be measured in postmortem blood samples?
可以在死后血液样本中测量帕金森综合症的诊断生物标志物吗?
  • 批准号:
    10572535
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
Investigation of the Effect of Structural Modifications of Tau on Assembly State and Seeding
Tau 结构修饰对组装状态和播种影响的研究
  • 批准号:
    10241797
  • 财政年份:
    2017
  • 资助金额:
    $ 237.47万
  • 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
  • 批准号:
    9267131
  • 财政年份:
    2015
  • 资助金额:
    $ 237.47万
  • 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
  • 批准号:
    9139393
  • 财政年份:
    2015
  • 资助金额:
    $ 237.47万
  • 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
  • 批准号:
    9331297
  • 财政年份:
    2015
  • 资助金额:
    $ 237.47万
  • 项目类别:
Novel Specific Ligands for ABeta Oligomers
Aβ 低聚物的新型特异性配体
  • 批准号:
    7296776
  • 财政年份:
    2007
  • 资助金额:
    $ 237.47万
  • 项目类别:
Novel Specific Ligands for ABeta Oligomers
Aβ 低聚物的新型特异性配体
  • 批准号:
    7486743
  • 财政年份:
    2007
  • 资助金额:
    $ 237.47万
  • 项目类别:
DEVELOPMENT AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
淀粉样 B 蛋白寡聚化抑制剂
  • 批准号:
    7112795
  • 财政年份:
    2006
  • 资助金额:
    $ 237.47万
  • 项目类别:
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
B 淀粉样蛋白寡聚化抑制剂的开发
  • 批准号:
    8114005
  • 财政年份:
  • 资助金额:
    $ 237.47万
  • 项目类别:
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
B 淀粉样蛋白寡聚化抑制剂的开发
  • 批准号:
    7663803
  • 财政年份:
  • 资助金额:
    $ 237.47万
  • 项目类别:

相似海外基金

A study for cross borders Indonesian nurses and care workers: Case of Japan-Indonesia Economic Partnership Agreement
针对跨境印度尼西亚护士和护理人员的研究:日本-印度尼西亚经济伙伴关系协定的案例
  • 批准号:
    22KJ0334
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Challenges of the Paris Agreement Exposed by the Energy Shift by External Factors: The Case of Renewable Energy Policies in Japan, the U.S., and the EU
外部因素导致的能源转移对《巴黎协定》的挑战:以日本、美国和欧盟的可再生能源政策为例
  • 批准号:
    23H00770
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
NSF-NOAA Interagency Agreement (IAA) for the Global Oscillations Network Group (GONG)
NSF-NOAA 全球振荡网络组 (GONG) 机构间协议 (IAA)
  • 批准号:
    2410236
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Cooperative Agreement
Conditions for U.S. Agreement on the Closure of Contested Overseas Bases: Relations of Threat, Alliance and Base Alternatives
美国关于关闭有争议的海外基地协议的条件:威胁、联盟和基地替代方案的关系
  • 批准号:
    23K18762
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
MSI Smart Manufacturing Data Hub – Open Calls Grant Funding Agreement
MSI 智能制造数据中心 – 公开征集赠款资助协议
  • 批准号:
    900240
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Collaborative R&D
Continuation of Cooperative Agreement between U.S. Food and Drug Administration and S.C. Department of Health and Environmental Control (DHEC) for MFRPS Maintenance.
美国食品和药物管理局与南卡罗来纳州健康与环境控制部 (DHEC) 继续签订 MFRPS 维护合作协议。
  • 批准号:
    10829529
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
National Ecological Observatory Network Governing Cooperative Agreement
国家生态观测站网络治理合作协议
  • 批准号:
    2346114
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Cooperative Agreement
The Kansas Department of Agriculture's Flexible Funding Model Cooperative Agreement for MFRPS Maintenance, FPTF, and Special Project.
堪萨斯州农业部针对 MFRPS 维护、FPTF 和特别项目的灵活资助模式合作协议。
  • 批准号:
    10828588
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
Robust approaches for the analysis of agreement between clinical measurements: development of guidance and software tools for researchers
分析临床测量之间一致性的稳健方法:为研究人员开发指南和软件工具
  • 批准号:
    MR/X029301/1
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Research Grant
Doctoral Dissertation Research: Linguistic transfer in a contact variety of Spanish: Gender agreement production and attitudes
博士论文研究:西班牙语接触变体中的语言迁移:性别协议的产生和态度
  • 批准号:
    2234506
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了